BergenBio Fundamentale Forhold (BGBIO)

[TekBot]

BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients

• The Company will discuss the topline results during its Q4 2022 results
  presentation on Thursday, February 16, 2023, at 10:00 AM CET -

…

Vis børsmeldingen

BERGEN, Norway, February 15, 2023 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, today announced topline data from BGBC008, a phase 2
trial evaluating its lead compound bemcentinib in combination with MSD’s anti-PD
-1 therapy pembrolizumab in 2L+ Non-Small Cell Lung Cancer (NSCLC) patients.

BGBC008 Topline Data

The open-label, multi-center, single arm, multi-cohort, international phase 2
trial conducted in collaboration with MSD (Merck and Co., Inc. Rahway, NJ, USA),
enrolled 90 evaluable patients with disease progression at study entry, who had
received at least one prior line of chemotherapy, immunotherapy, or the
combination. Enrolled patients received the combination of bemcentinib and
pembrolizumab until disease progression as assessed by investigators. Topline
results from the total evaluable population:

· A clinically meaningful survival benefit and evidence of disease control was
demonstrated with bemcentinib in combination with pembrolizumab regardless of
prior therapy, providing a median overall survival (mOS) of 13.0 months (95% CI:
10.1, 16.7), median progression free survival (mPFS) of 6.2 months (95% CI: 4.6,
9.8), disease control rate (DCR) of 51.1% (95% CI: 40.3, 61.8) and overall
response rate (ORR) of 11.1% (95% CI: 6.2, 18.1).

· A significant (p-value < 0.05) and clinically meaningful improvement in mOS
based on AXL tumor proportion score (TPS) was observed. Patients with AXL TPS >
5 (46% of evaluable patients) achieved a mOS of 14.8 months (95% CI: 12.4, 29.6)
compared to patients with AXL TPS < 5, who achieved a mOS of 9.9 months (95% CI:
6.7, 17.4). In addition, patients with an AXL TPS > 5 had a mPFS of 8.7 months
(95% CI: 6.0, 14.8) compared to 4.6 months (95% CI: 2.7, 8.1) for patients with
AXL TPS < 5. The ORR for AXL TPS > 5 was 21.9%.

· The observed mOS was similar regardless of patient PD-L1 status.

· Treatment with bemcentinib in combination with pembrolizumab was well
-tolerated.

“We are very encouraged by the topline data” said Martin Olin, Chief Executive
Officer of BerGenBio. “Treatment with bemcentinib in combination with
pembrolizumab demonstrated long survival benefit and sustained disease control,
particularly in patients with AXL TPS > 5, substantiating the relevance of AXL
as a target and bemcentinib’s selective inhibition capabilities in NSCLC.
Notably, the survival benefit was observed regardless of PD-L1 status. The data
support our ongoing phase 1b/2a trial in 1L STK11m NSCLC patients, of whom
approximately 80% have AXL expression. This subgroup of NSCLC represents more
than 30,000 patients in the US and five largest European countries, for whom
there is currently no effective targeted therapy available.”

James Spicer, PhD, FRCP, Professor of Experimental Cancer Medicine at King’s
College London and Principal Investigator of the BGBC008 trial, remarked, “The
reported data shows that the combination of bemcentinib and pembrolizumab is
well-tolerated in patients with NSCLC, and is particularly active in patients
with tumour AXL expression. Other evidence suggests that current therapies are
less effective in NSCLC with loss of the tumour suppressor gene STK11, and that
AXL inhibition can restore susceptibility. Further investigation is warranted to
confirm the role of AXL inhibition in STK11-mutated NSCLC patients, who are
under-served by currently available therapeutic options.”

The Company plans to present further details of the BCBG008 trial at an upcoming
medical conference.

First-Line STK11m NSCLC Trial (BGBC016)

BerGenBio is studying bemcentinib in a global, open-label, phase 1b/2a trial
evaluating bemcentinib in combination with the current standard of care of
pembrolizumab and platinum doublet chemotherapy, for the treatment of 1L NSCLC
patients with mutations in the STK11 gene. More than 30,000 NSCLC patients (US
and EU5) harbor STK11 mutations which are associated with poor prognosis with
currently available therapies. The Company believes that STK11 mutations create
a severely immunosuppressed tumor microenvironment associated with AXL
expression and activation, resulting in the development of drug resistance,
immune evasion, and metastases.

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / International Media Relations

Graham Morrell

graham.morrell@bergenbio.com

Media Relations Norway

Jan Lilleby

jl@lillebyfrisch.no

+47 90 55 16 98

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases. The Company is focused on advancing its lead candidate,
bemcentinib, a potentially first-in-class, oral, selective AXL inhibitor in
STK11 mutated NSCLC and severe respiratory infections including COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

About Bemcentinib

BerGenBio’s lead compound, bemcentinib, is a potentially first-in-class, oral,
selective inhibitor of the receptor tyrosine kinase AXL, which is expressed and
activated in response to oxidative stress, inflammation, hypoxia, and drug
treatment, resulting in a number of deleterious effects in cancer and severe
respiratory infections. Bemcentinib selectively inhibits AXL activation to
prevent the progression of serious diseases through the modulation of resistance
mechanisms and the adaptive immune system.

Bemcentinib is currently being developed in STK11 mutated NSCLC and severe
respiratory infections including COVID-19. Its novel mechanisms of action and
primary accumulation in the lungs uniquely position it to address these severe
lung diseases.

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and subject to the disclosure requirements pursuant to
section 5-12 of the Norwegian Securities Trading Act.

Kilde

[HJB]

Dette kan bli gøy

[Fartin]

Hva måles det opp mot? For eks:

overall
response rate (ORR) of 11.1% (95% CI: 6.2, 18.1

11% overall response rate høres jo svært lite ut. Men opp imot hva?

[Roc]

Grattis til BGBIO nye data på BEM

Hadde vært spennende å høre hva dere tenker og vurderer disse dataene. Følgende er litt mine førsteinntrykk. Disclaimer, jeg er ingen onkolog og heller ikke aksjonær.

Selve studiedesign:
Prospektiv, open label, enkel arm hvor 106 stk 2L NSCLC pasienter ble behandlet med BEM sammen med pembro hvor primærendepunktet var å se Objective Response Rate. Sekundærendepunkt nr 3 var Progression-free Survival (PFS) og sekundærendepunkt nr 4 var Overall survival.

Siden dette er en open label ikke-randomisert og ikke-kontrollert studie har selskapet hatt kjennskap til de dataene som er blitt generert mens studien pågikk. For eksempel i desember 2021 på DNB Healthcare konferansen ble det kommunisert at cohort A stage 2 (final analyse) var «complete», mens for cohort var final analyse ongoing og cohort 3 var ventet. Deretter, i april 2022 kommuniserte selskapet preliminære data fra STK11 pasienter fra denne studien og deretter i mai kom «laserfokus» hvor man bestemte seg for å forfølge STK11 NSCLC i en egen fase 1/2 studie. Om STK11 pasienter var en prespesifisert gruppe eller ad hoc funn er det vanskelig si for sikkert basert på offentlig tilgjengelig info siden protokollen og statistisk analyse plan for studien ikke er delt. Fra ct.gov er ikke STK11 prespesifisert. Uansett, basert på de tidlige dataene fra BGBC008 så hadde selskapet for ca 1 år siden lagt plan for videre strategi.

Primærendepunktet på BGBC008 studien ble i dag rapportert til overall response rate (ORR) of 11.1% (95% CI: 6.2, 18.1), mens de sekundære endepunkter som ble delt i pressemeldinger var: mOS of 13.0 months (95% CI: 10.1, 16.7), mPFS of 6.2 months (95% CI: 4.6, 9.8) og disease control rate (DCR) of 51.1% (95% CI: 40.3, 61.8).

Siden det ikke er en kontroll arm (for eksempel pembro/nivo) så finner jeg det litt vanskelig å si noe konkret om dataene (er som nevnt ikke onkolog) slik de foreligger alene, men føler det hjelper å sammenlikne med historiske kontroller.

Studier jeg klarer å finne som kanskje er de som likner best BGBC008 dvs 2L NSCLC stage IIIB eller IV inkl respektive resultater er summert under. Opp til enhver å sammenlikne BGBC008 data opp mot hva som oppnås med CPI alene:

Arrieta et al 2020 JAMA Oncol: Pembro + Docetaxel vs Docetaxel alene 2L NSCLC

• A statistically significant difference in ORR […] was found in patients receiving pembrolizumab plus docetaxel vs patients receiving docetaxel (42.5% vs 15.8%; odds ratio, 3.94; 95% CI, 1.34-11.54; P = .01).
• Overall, PFS was longer in patients who received pembrolizumab plus docetaxel (9.5 months; 95% CI, 4.2-not reached) than in patients who received docetaxel (3.9 months; 95% CI, 3.2-5.7) (hazard ratio, 0.24; 95% CI, 0.13-0.46; P < .001).
• mOS ikke oppgitt fordi antall events (dødsfall) på 45 ikke var oppnådd per protokoll

Borghaei et al NEJM 2015 (CheckMate-057): Nivo vs Decetaxel i avansert NSCLC

• mOS was 12.2 months (95% confidence interval [CI], 9.7 to 15.0) among 292 patients in the nivolumab group and 9.4 months (95% CI, 8.1 to 10.7) among 290 patients in the docetaxel group (hazard ratio for death, 0.73; 96% CI, 0.59 to 0.89; P=0.002).
• At 1 year, the overall survival rate was 51% (95% CI, 45 to 56) with nivolumab versus 39% (95% CI, 33 to 45) with docetaxel.
• The response rate was 19% with nivolumab versus 12% with docetaxel (P=0.02)
• Although progression-free survival did not favor nivolumab over docetaxel (median, 2.3 months and 4.2 months, respectively), the rate of progression-free survival at 1 year was higher with nivolumab than with docetaxel (19% and 8%, respectively)

Wu et al J Thor Oncol 2019 (CheckMate-078): Nivo vs Docetaxel i kinesiske pasienter

• OS was significantly improved with nivolumab (n = 338) versus docetaxel (n = 166); median OS (95% confidence interval): 12.0 (10.4–14.0) versus 9.6 (7.6–11.2) months, respectively; hazard ratio (97.7% confidence interval): 0.68 (0.52–0.90); p = 0.0006.
• Objective response rate was 17% with nivolumab versus 4% with docetaxel; median duration of response was not reached versus 5.3 months. Minimum follow-up was 8.8 months. The frequency of grade 3 or greater treatment-related adverse events was 10% with nivolumab and 48% with docetaxel.

At selskapet nå går videre spesifikt i STK11 subgruppen og ikke ikke-småcellet lungecarsinom i sin helhet tolker jeg som at de tenker det er her det er verdt å forfølge. Vi får vente på STK11 studien som avleses 1H 2025.

Ellers håper jeg AML studien også kommer med topplinje snart. Denne studien var ferdig ca 6 mndr før NSCLC studien og etter å ha tittet litt i gamle sides synes jeg følgende virket lovende (tatt fra selskapsoppdatering april 2021):

[TekBot]

BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update

BERGEN, Norway, February 16, 2023 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, today announced financial results for the fourth
…

Vis børsmeldingen

quarter ended December 31, 2022, and provided a business update.

A briefing by BerGenBio’s senior management team will take place at 10:00 am CET
today via a webcast presentation, followed by a Q&A session. Please see below
for details.

“The recent announcement of the topline data from our BCBG008 NSCLC trial
corroborates the strategy we enacted and the great strides we took in 2022,”
said Martin Olin, Chief Executive Officer of BerGenBio. “The trial showed a
survival benefit and disease control provided by bemcentinib in combination with
pembrolizumab, substantiating the relevance of AXL inhibition in NSCLC,
particularly in patients with AXL-expressing tumors. The results of the trial
strongly support our efforts to treat 1L NSCLC patients harboring STK11
mutations, a group in which AXL expression commonly occurs. Bemcentinib’s
ability to selectively inhibit AXL may serve as a key component in delivering
hope to this large, hard-to-treat patient population.”

Clinical Development

Bemcentinib

BerGenBio’s lead compound, bemcentinib, is a potentially first-in-class, oral,
highly selective inhibitor of the receptor tyrosine kinase AXL, which is
expressed and activated in response to oxidative stress, inflammation, hypoxia,
and drug treatment, resulting in a number of deleterious effects in cancer and
severe respiratory infections. Bemcentinib selectively inhibits AXL activation
to prevent the progression of serious diseases through the modulation of
resistance mechanisms and the adaptive immune system.

Bemcentinib is currently being developed in STK11 mutated NSCLC and severe
respiratory infections including COVID-19. Its novel mechanisms of action and
primary accumulation in the lungs uniquely position it to address these severe
lung diseases.

Oncology: NSCLC

2L+ NSCLC Trial (BGBC008)

Subsequent to quarter end, the Company announced topline data from the BGBC008
(2L+) NSCLC trial on February 15, 2023. The trial enrolled 90 evaluable patients
who received at least one prior line of therapy: chemotherapy, immunotherapy or
the combination. Topline results from the total evaluable population:

· A clinically meaningful survival benefit and evidence of disease control was
demonstrated with bemcentinib in combination with pembrolizumab regardless of
prior therapy, providing a median overall survival (mOS) of 13.0 months (95% CI:
10.1, 16.7), median progression free survival (mPFS) of 6.2 months (95% CI: 4.6,
9.8), disease control rate (DCR) of 51.1% (95% CI: 40.3, 61.8) and overall
response rate (ORR) of 11.1% (95% CI: 6.2, 18.1).

· A significant (p-value < 0.05) and clinically meaningful improvement in mOS
based on AXL tumor proportion score (TPS) was observed. Patients with AXL TPS >
5 (46% of evaluable patients) achieved a mOS of 14.8 months (95% CI: 12.4, 29.6)
compared to patients with AXL TPS < 5, who achieved a mOS of 9.9 months (95% CI:
6.7, 17.4). In addition, patients with an AXL TPS > 5 had a mPFS of 8.7 months
(95% CI: 6.0, 14.8) compared to 4.6 months (95% CI: 2.7, 8.1) for patients with
AXL TPS < 5. The ORR for AXL TPS > 5 was 21.9%.

· The observed mOS was similar regardless of patient PD-L1 status.

· Treatment with bemcentinib in combination with pembrolizumab was well
-tolerated.

2L+ NSCLC Trial (BGBIL005)

In addition to the encouraging ORR and DCR data previously presented from the
Investigator Led Study phase 1 trial in which bemcentinib was combined with
docetaxel, the final mPFS of 3.1 months and mOS of 12.3 months support the
clinical benefit of combining bemcentinib with chemotherapy.

1L STK11m NSCLC (BGBC016)

BerGenBio announced in October 2022 the initiation of a global, open label phase
1b/2a trial evaluating bemcentinib in combination with the current standard of
care, pembrolizumab and platinum doublet chemotherapy, for the treatment of 1L
NSCLC patients harboring STK11 mutations. The trial is designed to determine the
safety, tolerability, and efficacy of bemcentinib with standard of care in 1L
advanced/metastatic non-squamous NSCLC patients with STK11 mutations and no
other actionable co-mutations.

A significant subgroup comprising approximately 20% (> 30,000 patients in US and
EU5) of non-squamous NSCLC patients harbor STK11 mutations, which are associated
with immunosuppression and poor prognosis with standard treatment in 1L NSCLC.
Data suggests that STK11m NSCLC patients almost universally have AXL tumor
expression and activation, resulting in the development of drug resistance,
immune evasion, and metastases.

Topline data from the 2L+ NSCLC (BGBC008) trial show clinically meaningful mOS,
mPFS and DCR with the combination of bemcentinib and pembrolizumab, regardless
of prior therapy. In patients with an AXL TPS > 5, a clinically significant
improvement in mOS was observed providing supporting evidence for the relevance
of AXL inhibition in the treatment of NSCLC. Further, data from the 2L+ NSCLC
(BGBIL005) trial indicated promising clinical benefits from administering
bemcentinib with chemotherapy.

The results of the BCBG008 and BCBIL005 trials provide clinical evidence of the
anti-tumor effects of bemcentinib and its ability to modulate the tumor
microenvironment to enhance the effects of immunotherapy and chemotherapy and
provide strong support for the ongoing 1L NSCLC trial in patients harboring
STK11 mutations, that are characterized by a severely immunosuppressed, pro
-tumorigenic microenvironment and AXL activation.

Screening of patients for the 1L STK11m NSCLC (BCBG016) trial is ongoing.

Oncology: Relapsed/Refractory AML

As previously announced, the Company expects to report topline results from the
phase 2 BGBC003 trial in Relapsed/Refractory AML in H1 2023.

Severe Respiratory Infections (SRIs)

The Company believes that bemcentinibblocks viral entry and replication,
stimulates the innate immune system, and promotes lung tissue repair positioning
it for the treatment of severe respiratory infections including COVID-19.

Previously the Company has completed two phase 2 trials with bemcentinib in
hospitalized COVID-19 patients, showing promising clinical activity and is
currently enrolling patients into theEUSolidActphase 2b platform trial in
hospitalized COVID-19 patients.

The trial is sponsored,and majority funded by the EUSolidAct platform, a pan
-European research project designed to investigate treatment options for
hospitalized patients with COVID-19 and emerging infectious diseases. Thesponsor
and theCompany are currently monitoring the evolution of thepandemic and its
impact on the trial execution.Further guidance on the trial is expected in
H12023.

Additionally, bemcentinib is being evaluated in preclinical studies for SRIs
causingAcute Respiratory Distress Syndrome (ARDS) and initial results are
expected during 2023.

Corporate Activities

Shareholder Loan Facility

BerGenBio announced in October that it secured a shareholder loan facility of up
to NOK 100 million from Meteva AS, a 27.23% shareholder in BerGenBio. The
Company can draw on the facility from Q2 2023. In addition to the Company’s
existing cash position, the facility will enable BerGenBio to continue advancing
its lead compound, bemcentinib, in 1L STK11m NSCLC and hospitalized COVID-19
patients.

Oncology Scientific Advisory Board

Subsequent to the quarter end, BerGenBio announced in February the formation of
a scientific advisory board to enhance the development of bemcentinib for the
treatment of NSCLC patients with STK11m, consisting of four world-renowned non
-small cell lung cancer experts from top oncology centers around the globe:
Enriqueta Felip, M.D., Ph.D., Head of the Thoracic Cancer Unit at Vall d’Hebron
University Hospital, Spain; John Heymach, M.D., Ph.D., Chair of Thoracic/Head
and Neck Medical Oncology at the MD Anderson Cancer Center, Texas; Tony Mok,
M.D., BMSc., Professor and Chairman of the Department of Clinical Oncology at
the Chinese University of Hong Kong; and Solange Peters, M.D., Ph.D., Professor
and Head of Medical Oncology and Thoracic Malignancies at the Department of
Oncology at Lausanne University, Switzerland.

Fourth Quarter 2022 and Full Year Financial Highlights

(Figures in brackets = same period 2021 unless otherwise stated)

•      Revenue amounted to NOK 0.4 million (NOK 0.8 million) for the fourth
  

quarter and NOK 0.4 million (NOK 0.8 million) for the full year 2022

•      Total operating expenses for the fourth quarter were NOK 76.8 million
  

(NOK 68.1 million) and total operating expenses for the full year 2022 amounted
to 306.0 million (NOK 315.2 million)

•      The operating loss for the quarter came to NOK 76.4 million (NOK 67.3
  

million) and NOK 305.6 million (NOK 314.5 million) for the full year 2022

•      Cash and cash equivalents amounted to NOK 150.8 million at the end of
  

December 2022 (NOK 436.6 million by end of December 2021). The cash position in
addition to the shareholder loan facility secured from Meteva AS of up to NOK
100 million is estimated to fund planned activities through 2023 on a going
concern basis.

Webcast Details

The live webcast link is available at www.bergenbio.com in the
Investors/Financial Reports section. A recording will be available shortly after
the webcast has finished.

Webcast
link: https://channel.royalcast.com/landingpage/hegnarmedia/20230216_14/ (https:/
/eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fchannel.royalcast.com%
2Flandingpage%2Fhegnarmedia%2F20230216_14%2F&data=05%7C01%7Crune.skeie%40bergenbi
o.com%7Cb823a5a1341740f421a708db02b68023%7C2b50b422ca6d42af9fc0741b248bb071%7C0%7
C0%7C638106755093046661%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luM
zIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=5chsFpg9akBDMyUY7AI7ugQ8X
Ntq4PCq9giLgrjKS9w%3D&reserved=0)

Dial-in numbers:

NO: +47-21-956342

UK: +44-203-7696819

US: +1 646-787-0157

SE: +46-4-0682-0620

DK: +45 78768490

Pin: 712491

The fourth quarter and full year report and presentation are available on the
Company’s website in the Investors/Financial Reports section.

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / International Media Relations

Graham Morrell

graham.morrell@bergenbio.com

Media Relations Norway

Jan Lilleby

jl@lillebyfrisch.no

+47 90 55 16 98

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases. The Company is focused on advancing its lead candidate,
bemcentinib, a potentially first-in-class, oral, selective AXL inhibitor in
STK11 mutated NSCLC and severe respiratory infections including COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and subject to the disclosure requirements pursuant to
section 5-12 of the Norwegian Securities Trading Act.

Kilde

[Tekspert]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @anon95652491 (112 likes)

@anon95652491

Triggerliste/hendelser (sortert nyeste først):

2. @Matadoren (63 likes)

@Matadoren

Jeg ser at dette Narrativet at Mohn og hans rådgivere ikke har ekspertise på medisinsk forskning, og at Mohn kaster penger etter BergenBio for å støtte nærmiljøet dukker opp med jevne mellomrom.

3. @Roc (44 likes)

@Roc

Grattis til BGBIO nye data på BEM

Resten av topp 10:

4. @Zuba (33 likes)

5. @Hotdog (30 likes)

6. @Hayen (25 likes)

7. @drdr (24 likes)

8. @PankPinter (24 likes)

9. @Bonus (19 likes)

10. @keislar (11 likes)

Gratulerer!

[TekBot]

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

• Global trial designed to study the safety, tolerability and efficacy of
  bemcentinib in combination with current standard of care -

…

Vis børsmeldingen

BERGEN, Norway, March 9, 2023 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, today announced the first patient was dosed in a
Phase 1b/2a trial evaluating bemcentinib in combination with the current
standard of care, immune checkpoint inhibitor pembrolizumab and doublet
chemotherapy, for the treatment of 1st line (1L) Non-Small Cell Lung Cancer
(NSCLC) patients harboring STK11 mutations (STK11m).

“Approximately 20% of non-squamous NSCLC patients harbor STK11m and do not
currently have effective treatment options,” said Martin Olin, Chief Executive
Officer of BerGenBio. “One specific attribute of this group is that they almost
all demonstrate high levels of AXL activation. We are elated to have dosed the
first patient in our trial and to continue our evaluation of bemcentinib and its
ability to inhibit AXL to revive STK11m NSCLC patients’ response to checkpoint
inhibitors and chemotherapy.”

The trial’s lead investigator, Rajwanth Veluswamy, M.D., MSCR, Assistant
Professor of Medicine, Hematology and Medical Oncology, Icahn School of Medicine
at Mount Sinai (New York, NY), commented, “Today, STK11 mutations are correlated
with a very poor prognosis for patients suffering from NSCLC. These mutations
are widely recognized for their ability to impede the activity of anti-PD-1/L1
therapy. My colleagues and I are driven to find a better outcome for this large
patient population and are eager to assess bemcentinib’s potential in achieving
this goal.”

The global, open-label Phase 1b/2a trial is designed to determine the safety,
tolerability and efficacy of bemcentinib with standard of care treatments in
untreated advanced/metastatic non-squamous NSCLC patients with STK11 mutations
and no actionable mutations. The Phase 1b portion of the study will evaluate the
safety and feasibility of bemcentinib in combination with pembrolizumab and
doublet chemotherapy in 1L advanced/metastatic non-squamous NSCLC patients,
regardless of STK11 status. The Phase 2a expansion part will assess the efficacy
of bemcentinib in the same treatment combination in 1L advanced/metastatic non
-squamous NSCLC patients with STK11 mutations.

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / Media Relations

Graham Morrell

graham.morrell@bergenbio.com

Media Relations Norway

Jan Lilleby

jl@lillebyfrisch.no

+47 90 55 16 98

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases. The Company is focused on advancing its lead candidate,
bemcentinib, a potentially first-in-class, oral, selective AXL inhibitor in
STK11 mutated NSCLC and severe respiratory infections including COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BerGenBio to Present at Upcoming Scientific Conferences

• Data on AXL as a therapeutic target in lung cancers to be highlighted at AACR

…

Vis børsmeldingen

• Ph1a/2b 1L STK11m NSCLC trial design to be outlined at ELCC -

BERGEN, Norway, March 28,2023 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, today announced that the Company will be presenting
three posters at two upcoming scientific conferences: ESMO’s European Lung
Cancer Congress (ELCC) 2023 and the American Association for Cancer Research
(AACR) Annual Meeting 2023.

European Lung Cancer Conference 2023

March 29 - April 1, 2023

Bella Center - Copenhagen, Denmark

Poster Title: Phase 1b/2a safety and tolerability study of bemcentinib with
pembrolizumab/carboplatin/pemetrexed in subjects with untreated advanced or
metastatic non-squamous NSCLC with/without STK11
mutations (https://cslide.ctimeetingtech.com/elcc23hybrid/attendee/confcal/presen
tation/list?q=78TiP)

Session Title: Poster Display session (ID 51)

Session Date & Time: Friday March 31, 2023, 12:00 PM - 12:45 PM

Location: Exhibition and Poster area

Presentation Number: 78TiP

American Association for Cancer Research Annual Meeting 2023

April 14 - 19, 2023

Orlando County Convention Center - Orlando, Florida

Poster Title:?AXL as a Therapeutic Target in STK11 mutant
NSCL (Program Planner)C
Session Title:?Combination Immunotherapies 1
Session Date and Time:?Monday Apr 17, 2023, 1:30 PM - 5:00 PM
Location:?Section 39
Poster Board Number:?18
Abstract Presentation Number:?3245

Poster Title:? Combined inhibition of AXL and ATR enhances replication stress,
cell death and immune response in small cell lung
cancer (Program Planner)
Session Title:? DNA Repair / Molecular Classification of Tumors for Diagnostics,
Prognostics, and Therapeutic Outcomes
Session Date and Time:?Wednesday Apr 19, 2023, 9:00 AM - 12:30 PM
Location:?Section 18
Poster Board Number:?8
Abstract Presentation Number:?6206

The posters from both conferences will be available on the Company’s website in
the Scientific
Presentations (Presentations - BerGenBio) portion of
the Investors section following their presentations.

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / Media Relations

Graham Morrell

graham.morrell@bergenbio.com

Media Relations Norway

Jan Lilleby

jl@lillebyfrisch.no

+47 90 55 16 98

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[Tekspert]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @Matadoren (60 likes)

@Matadoren

Jeg ser at dette Narrativet at Mohn og hans rådgivere ikke har ekspertise på medisinsk forskning, og at Mohn kaster penger etter BergenBio for å støtte nærmiljøet dukker opp med jevne mellomrom.

2. @Roc (54 likes)

@Roc

Grattis til BGBIO nye data på BEM

3. @Hotdog (37 likes)

@Hotdog

NewsWeb

Resten av topp 10:

4. @Zuba (33 likes)

5. @Bonus (23 likes)

6. @anon8907229 (22 likes)

7. @PankPinter (19 likes)

8. @keislar (16 likes)

9. @drdr (15 likes)

10. @laplagam (11 likes)

Gratulerer!

[TekBot]

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR

• In addition to STK11 mutations, KEAP1m identified as being associated with
  STK11 loss of function -

…

Vis børsmeldingen

• STK11 loss of function correlated to AXL activation and poorer outcomes in
  NSCLC -

BERGEN, Norway, April 18, 2023 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, today announced that it presented data linking AXL
activation to STK11 loss of function in Non-Small Cell Lung Cancer (NSCLC) in an
abstract titled, AXL as a Therapeutic Target in STK11 mutant NSCLC, at the
American Association for Cancer Research (AACR) Annual Meeting 2023.

An analysis of tumors lacking STK11 function from BerGenBio’s 2nd line NSCLC
trial (BGBC008) and publicly available datasets suggest that STK11 and KEAP1
mutations are transcriptionally similar and share a common signature for STK11
loss of function. Loss of function leading to inactivation of STK11 is found in
approximately 30% of lung adenocarcinomas as a result of both mutational and non
-mutational mechanisms. These tumors with inactivated STK11 are likely to
promote AXL activation due to high levels of energetic and metabolic stress,
resulting in a poorer prognosis in NSCLC.

AXL, a member of the TAM family of receptor tyrosine kinases, is expressed in
over 80% of NSCLC tumors that demonstrate loss of STK11 function. AXL is
activated in response to inflammation, hypoxia, cellular stress or drug
treatment. AXL is expressed in both tumor cells, where it enhances survival and
drug resistance, and in innate immune cells, such as dendritic cells and
macrophages, where AXL drives immune suppression. BerGenBio’s selective AXL
inhibitor bemcentinib targets key survival and resistance mechanisms within the
tumor and restores the anti-tumor characteristics of innate immune cells within
the tumor microenvironment.

“There is accumulating evidence substantiating the importance of targeting AXL
within the tumor and innate immune cells of the tumor microenvironment,” said
Nigel McCracken,Ph.D., Chief Scientific Officer of BerGenBio. “A loss of STK11
function due to STK11 or KEAP1 mutations is associated with a poorer prognosis,
irrespective of treatment modality and represents a large subgroup of NSCLC
patients with high unmet need. Our preclinical data and the clinical data from
our Phase 2 trial evaluating bemcentinib in combination with pembrolizumab
support targeting AXL in both STK11 and KEAP1 mutated NSCLC patients.”

The abstract will be available on the Company’s website in the Scientific
Presentations (Presentations - BerGenBio) portion of
the Investors section.

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / Media Relations

Graham Morrell

graham.morrell@bergenbio.com

Media Relations Norway

Jan Lilleby

jl@lillebyfrisch.no

+47 90 55 16 98

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visitwww.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BerGenBio ASA: Foreslår delvis garantert fortrinnsrettsemisjon

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT

Bergen, 25. april 2023: Styret i BerGenBio ASA («Selskapet») har i dag, med
forbehold om godkjenning av den ordinære generalforsamlingen
(«Generalforsamlingen») den 22. mai 2023, vedtatt å gjennomføre en
fortrinnsrettsemisjon med aksjer (“Nye Aksjer”) med fortrinnsrett for
eksisterende aksjonærer (“Fortrinnsrettsemisjonen”) for å hente inn et
bruttoproveny inntil 250 millioner NOK. For hver andre Nye Aksje som tegnes i
Fortrinnsrettsemisjonen vil man motta frittstående tegningsrett på én ny aksje i
Selskapet («Frittstående Tegningsrett»). Etterfølgende utøvelse av Frittstående
Tegningsretter vil øke bruttoprovenyet til Selskapet.
Enkelte eksisterende aksjonærer og eksterne investorer («Garantistene») har
garantert for tegning av NOK 175 millioner. Noen eksisterende aksjonærer,
inkludert Meteva AS og Investinor AS, har på forhånd forpliktet seg til å tegne
for henholdsvis NOK 65 millioner og NOK 17,5 millioner. I tillegg vil Selskapets
ledelse og styremedlemmer i Selskapet vil tegne Nye Aksjer i
Fortrinnsrettsemisjonen med et samlet tegningsbeløp på minst 0,5 millioner NOK.

Nettoprovenyet fra Fortrinnsrettsemisjonen og Frittstående Tegningsretter som
har blitt utøvet vil bli benyttet til å fremme Selskapets strategi for ikke
-småcellet lungekreft («NSCLC»), alvorlige luftveisinfeksjoner og generelle
selskapsformål. Etter å ha vurdert den betydelige reduksjonen i
sykehusinnleggelser som følge av COVID-19 i vintersesongen 2022-23, har EU
-SolidAct Trial Steering Committee i overenstemmelse med Selskapet besluttet å
sette denne studien på pause inntil en potensiell akselerasjon i COVID-19
sykehusinnleggelser krever ytterligere evaluering av bemcentinib i denne
populasjonen.

Innkalling til Generalforsamlingen, inkludert forslag til vedtak angående
Fortrinnsrettsemisjonen, forventes sendt til aksjonærene 28. april 2023.

Arctic Securities AS og Carnegie AS er engasjert som tilretteleggere i
Fortrinnsrettsemisjonen (“Tilretteleggerne”). H.C. Wainwright & Co. er engasjert
som finansiell rådgiver til Selskapet. Advokatfirmaet Thommessen AS er juridisk
rådgiver for Selskapet i forbindelse med Fortrinnsrettsemisjonen.

Garantier

I henhold til, og underlagt, vilkårene og betingelsene i garantiavtalene mellom
Selskapet og Garantistene (“Garantiavtalene”) har Garantistene forpliktet seg på
pro-rata-basis (ikke i fellesskap) å garantere for tegning av aksjer i
Fortrinnsrettsemisjonen med et samlet tegningsbeløp på NOK 175 millioner («Total
Garantiforpliktelse»), med forbehold om en potensiell reduksjon for Meteva AS
som beskrevet nedenfor. Eventuelle Nye Aksjer tegnet i Fortrinnsrettsemisjonen
vil redusere Total Garantiforpliktelse, men ikke forhåndstegninger fra
eksisterende aksjonærer.

Hver Garantist har rett på et garantihonorar på 12 % av sin respektive
garantiforpliktelse, som skal gjøres opp i kontanter, eller nye aksjer i
Selskapet utstedt til tegningskursen i Fortrinnsrettsemisjonen, eller som en
kombinasjon av kontanter og nye aksjer etter Garantistens valg. Utvalget av
aksjonærer som har blitt invitert til å garantere har vært basert på objektive
kriterier.

Garantistene har forpliktet seg til å stemme for Fortrinnsrettsemisjonen med
alle aksjer de har på tidspunktet for Generalforsamlingen.

Meteva AS sin garanti og forhåndstilsagn om å tegne Nye Aksjer er begrenset slik
at Meteva AS sitt eierskap til aksjer i Selskapet ikke skal overstige 1/3, og at
eventuelle gjenværende garanti- og forhåndsforpliktelser skal gjøres opp i form
av et konvertibelt lån fra Meteva AS. Et slikt konvertibelt lån skal kunne
konverteres til aksjer i Selskapet til en konverteringskurs lik tegningskursen i
Fortrinnsrettsemisjonen og ellers på vilkår tilsvarende de i eksisterende
låneavtaler mellom Selskapet og Meteva AS, annonsert ved Selskapets børsmelding
25. oktober 2022 («Meteva-lånet»).

Tegningskurs, tegningsretter, Frittstående Tegningsretter og proveny

Tegningskursen for de Nye Aksjene som skal utstedes i Fortrinnsrettsemisjonen,
og dermed det nøyaktige antallet Nye Aksjer og det nøyaktige beløpet for
aksjekapitalforhøyelsen, vil bli foreslått av styret, basert på en anbefaling
fra Tilretteleggerne, dagen før Generalforsamlingen. I henhold til
Garantiavtalene skal tegningskursen i Fortrinnsrettemisjonen være den teoretiske
ex-rettighetskursen (TERP) basert på volumvektet gjennomsnittspris (VWAP) på
Selskapets aksjer på Oslo Børs de tre handelsdagene før Generalforsamlingen,
fratrukket en rabatt på minst 37,5 %. Styrets vedtak i denne forbindelse vil bli
kunngjort gjennom en børsmelding dagen før Generalforsamlingen og vil
reflekteres i det endelige forslag til vedtak for Generalforsamlingen.

I henhold til allmennaksjeloven §10-4 vil Selskapets aksjonærer på tidspunktet
for generalforsamlingen, som ikke er hjemmehørende i en jurisdiksjon hvor et
slik tilbud vil være ulovlig eller (i andre jurisdiksjoner enn Norge) kreve
prospekt, innsendelse, registrering eller lignende handling, gis fortrinnsrett
til å tegne og tildeles de Nye Aksjene i forhold til antall aksjer i Selskapet
de eier på den datoen, og vil i tråd med styrets forslag motta tegningsretter
proporsjonalt med deres eksisterende aksjeinnehav som registrert i Selskapets
aksjonærregister i Verdipapirsentralen (VPS) ved utløpet av 24. mai 2023. Gitt
at kjøp av aksjer er gjort med normalt T+2-oppgjør vil aksjer kjøpt til og med
22. mai 2023 gi rett til å motta tegningsretter, men aksjer kjøpt fra og med 23.
mai 2023 ikke vil gi rett til å motta tegningsretter. Tegningsrettene vil være
omsettelige og notert på Oslo Børs fra og med første dag i tegningsperioden og
frem til klokken 16:30 (Oslo-tid) to handelsdager før tegningsperiodens utløp.
Overtegning og tegning uten tegningsretter vil bli tillatt.

Tegnerne i Fortrinnsrettsemisjonen vil uten kostnad bli tildelt én Frittstående
Tegningsrett utstedt av Selskapet for hver to Nye Aksjer som tildeles og betales
av dem i Fortrinnsrettsemisjonen. Hver tegningsrett vil gi innehaveren rett til
å tegne én ny aksje i Selskapet til en tegningskurs lik volumveid
gjennomsnittskurs (VWAP) på selskapets aksjer på Oslo Børs de tre siste
handelsdagene før den første dato innehaveren kan utøve Frittstående
Tegningsrett fratrukket 30 %, men ikke høyere enn tegningskursen i
Fortrinnsrettsemisjonen pluss 30 %. De Frittstående Tegningsrettene kan utøves i
to perioder: i) i løpet av de første 14 dagene etter Selskapets kunngjøring av
kvartalsrapporten for 3. kvartal 2023 og ii) fra 1. april 2024 til 14. april
2024. Andre vilkår og betingelser for de Frittstående Tegningsrettene vil bli
fastsatt av Generalforsamlingen. Selskapet skal med rimelig innsats søke å sørge
for at de Frittstående Tegningsrettene tas opp til handel på en relevant
handelsplass så snart som mulig etter gjennomføring av Fortrinnsrettsemisjonen,
men det kan ikke gis noen garanti for at slikt opptak til handel vil bli
oppnådd.

Det maksimale bruttoprovenyet fra Fortrinnsrettsemisjonen vil være NOK 250
millioner og minimum NOK 175 millione (dog slik at en del av et slikt
bruttoproveny kan være i form av et konvertibelt lån fra Meteva AS som beskrevet
ovenfor). Dersom Selskapet trekker på det eksisterende Meteva-lånet før start av
tegningsperioden i Fortrinnsrettsemisjonen, har Meteva AS rett til å konvertere
det samlede trukne beløp til aksjer i Fortrinnsrettsemisjonen til tegningskursen
i Fortrinnsrettsemisjonen, og brutto kontantprovenyet fra
Fortrinnsrettsemisjonen vil i et slikt tilfelle bli tilsvarende redusert.

Bruttoprovenyet fra utøvelsen av Frittstående Tegningsretter vil avhenge av
antallet Frittstående Tegningsretter som er utstedt og utøvd, samt den endelige
utøvelsesprisen for de Frittstående Tegningsrettene, fastsatt som beskrevet
ovenfor.

Prospekt og indikativ tidslinje

I forbindelse med Fortrinnsrettsemisjonen vil det bli utarbeidet et prospekt
(«Prospektet») som er betinget av godkjenning fra Finanstilsynet, som er
forventet gitt 26. mai 2023. Prospektet vil bli offentliggjort før
tegningsperiodens begynnelse og vil danne grunnlag for tegninger i
Fortrinnsrettsemisjonen. Forutsatt at Prospektet godkjennes av Finanstilsynet i
tide, vil tegningsperioden for Fortrinnsrettsemisjonen starte 30. mai 2023 og
utløpe 13. juni 2023 klokken 16:30 (Oslo-tid). I tilfelle Prospektet ikke
godkjennes i tide til å opprettholde denne tegningsperioden, vil
tegningsperioden starte den andre handelsdagen på Oslo Børs etter godkjenningen
og utløpe klokken 16:30 (Oslo-tid) to uker deretter. En ytterligere beskrivelse
av Fortrinnsrettsemisjonen og andre forhold som må vurderes ved tegning av
aksjer i Fortrinnsrettsemisjonen vil bli inkludert i Prospektet.

Inntatt nedenfor er en indikativ tidslinje for Fortrinnsrettsemisjonen:

22. mai 2023: Ordinær generalforsamling

23. mai 2023: Siste handelsdag i aksjene inkludert tegningsretter

24. mai 2023: Første handelsdag i aksjene eksklusive tegningsretter

25. mai 2023: Eierregisterdato for fastsettelse av rett til å motta
    tegningsretter

På eller rundt 26. mai 2023: Offentliggjøring av Prospektet

30. mai 2023: Start av tegningsperioden og første dag for handel i
    tegningsrettene

På eller rundt 9. juni 2023: Siste dag for handel i tegningsrettene

På eller rundt 13. juni 2023: Siste dag i tegningsperioden

På eller rundt 14. juni 2023: Tildeling av de Nye Aksjene og Frittstående
Tegningsretter

På eller rundt 16. juni 2023: Betaling av de Nye Aksjene

På eller rundt 20. juni 2023: Registrering av aksjekapitalforhøyelsen i
Foretaksregisteret

For ytterligere informasjon, vennligst kontakt:

Martin Olin CEO, BerGenBio ASA
ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

Investor Relations / Media Relations

Graham Morrell
graham.morrell@bergenbio.com

Media Relations Norway

Jan Lilleby
jl@lillebyfrisch.no
+47 90 55 16 98

Denne informasjonen ansees som innsideinformasjon i henhold til EUs
markedsmisbruksforordning (MAR) og er underlagt offentliggjøringskravene i
henhold til MAR artikkel 17 og verdipapirhandelloven §5-12.

Denne børsmeldingen ble publisert av Rune Skeie, CFO, 25. april klokken 17:40
CEST, på vegne av Selskapet

Om BerGenBio

BerGenBio er et biofarmasøytisk selskap på klinisk nivå som fokuserer på å
utvikle transformative legemidler rettet mot AXL, som en potensiell hjørnestein
i behandling av aggressive sykdommer, inkludert kreft og alvorlige
luftveisinfeksjoner. Selskapet er fokusert på sin proprietære hovedkandidat
bemcentinib, en potensielt førsteklasses selektiv AXL-hemmer i utvikling for
STK11-muntert NSCLC og COVID-19.

BerGenBio er basert i Bergen, Norge med et datterselskap i Oxford,
Storbritannia. Selskapet er notert på Oslo Børs (ticker: BGBIO). For mer
informasjon, besøk www.bergenbio.com.

• IMPORTANT INFORMATION -

This announcement does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. Copies of this document may not be sent to
jurisdictions, or distributed in or sent from jurisdictions, in which this is
barred or prohibited by law. The securities of the Company may not be offered or
sold in the United States absent registration or an exemption from registration
under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”).
The securities of the Company have not been, and will not be, registered under
the U.S. Securities Act. Any sale in the United States of the securities
mentioned in this communication will be made solely to “qualified institutional
buyers” as defined in Rule 144A under the U.S. Securities Act. No public
offering of the securities will be made in the United States.

Any offering of the securities referred to in this announcement will be made by
means of the Prospectus. This announcement is an advertisement and is not a
prospectus for the purposes of Regulation (EU) 2017/1129 of the European
Parliament and of the Council of 14 June 2017 on prospectuses to be published
when securities are offered to the public or admitted to trading on a regulated
market, and repealing Directive 2003/71/EC (as amended) as implemented in any
EEA Member State (the “Prospectus Regulation”). Investors should not subscribe
for any securities referred to in this announcement except on the basis of
information contained in the Prospectus. Copies of the Prospectus will,
following publication, be available from the Company’s registered office and,
subject to certain exceptions, on the websites of the Managers.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation, i.e., only to investors who can receive the offer without
an approved prospectus in such EEA Member State.

In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). These materials are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

This document is not for publication or distribution in, directly or indirectly,
Australia, Canada, Japan, the United States or any other jurisdiction in which
such release, publication or distribution would be unlawful, and it does not
constitute an offer or invitation to subscribe for or purchase any securities in
such countries or in any other jurisdiction. In particular, the document and the
information contained herein should not be distributed or otherwise transmitted
into the United States or to publications with a general circulation in the
United States of America.

The Managers are acting for the Company in connection with the Rights Issue and
no one else and will not be responsible to anyone other than the Company for
providing the protections afforded to their respective clients or for providing
advice in relation to the Rights Issue or any transaction or arrangement
referred to in this announcement.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date and are
subject to change without notice. This announcement is made by and is the
responsibility of, the Company. Neither the Managers nor any of their respective
affiliates makes any representation as to the accuracy or completeness of this
announcement and none of them accepts any responsibility for the contents of
this announcement or any matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. No reliance may be
placed for any purpose on the information contained in this announcement or its
accuracy, fairness or completeness. Neither the Managers nor any of their
respective affiliates accepts any liability arising from the use of this
announcement.

Kilde

[TekBot]

BerGenBio ASA - Key information relating to the preferential rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT

Reference is made to the stock exchange announcement published by BerGenBio ASA
(the “Company”) earlier today, on 25 April 2023, regarding the resolution by the
Company’s board of directors to propose that the Company carries out a share
capital increase, by way of a partly underwritten rights issue, to raise gross
proceeds of up to NOK 250 million (the “Rights Issue”).

Date on which the terms and conditions of the preferential rights issue were
announced: 25 April 2023

Last day including right: 22 May 2023

Ex-date: 23 May 2023

Record Date: 24 May 2023

Date of approval: 22 May 2023

Maximum number of new shares: 2,500,000,000

Subscription price: Minimum NOK 0.10 and maximum NOK 10

Ratio preferential rights: To be announced when the final number of new shares
is determined

Subscription ratio: To be announced when the final number of new shares is
determined

Managers: Arctic Securities AS and Carnegie AS

Will the rights be listed: The Company will apply for listing of the
preferential rights on the Oslo Stock Exchange

ISIN for the preferential rights: To be announced when clarified

Other information: The subscription price for the new shares to be issued in the
Rights Issue, and thus the final number of new shares and the exact amount of
the share capital increase will be proposed by the board of directors, based on
a recommendation from the managers, the day prior to the annual general meeting
to be held on 22 May 2023 (the “AGM”). See the stock exchange announcement
published earlier today, on 25 April 2023, for further information regarding the
Rights Issue. The rights issue is subject to approval by the AGM. Notice of the
AGM will be sent on 28 April 2023.

This information is published in accordance with the requirements of the
Continuing Obligations.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / Media Relations

Graham Morrell

graham.morrell@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com.

Kilde

[Roc]

Var det såpass gode data på AACR at de kjører en emisjon 22. mai?

[TekBot]

BERGENBIO ASA: Board approval of 2022 Annual Financial Statement and Annual Report 2022

Bergen, Norway - 28 April 2023- BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL inhibitors for severe
unmet medical needs, announces that the Board of Directors today approved the
…

Vis børsmeldingen

2022 Annual Financial Statements prepared in accordance with International
Financial Reporting Standards (IFRS).

The Annual Report for 2022 in pdf and European Single Electronic Format (ESEF)
are attached to this release and are also available on BerGenBio ASA’s website
Financial Reports - BerGenBio

Contacts:

For BerGenBio: Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BERGENBIO ASA: Notice of Annual General Meeting

Bergen, Norway - 28 April 2023: BerGenBio ASA (OSE:BGBIO) will be holding its
Annual General Meeting virtually on 22 May 2022 at 16:00 hours (CEST).

…

Vis børsmeldingen

The notice, registration form, power of attorney and proposal from Nomination
Committee are attached to this release. The notice will be sent to all
registered shareholders and is available on the Company’s website:
General Meetings - BerGenBio

All shareholders are encouraged to exercise their shareholder rights, either
through advance electronically voting through VPS Investor Services, by using
the enclosed proxy form to provide proxy to the Chairman Anders Tullgren (or the
person he appoints), or to attend the general meeting virtually.
Advance vote or proxy for the Annual General Meeting can be registered through
the company’s website (General Meetings - BerGenBio) or
VPS Investor
Service (VPS GeneralMeeting
f59b30f3819&validTo=1687356000000&oppdragsId=20230424VPQ54GU0) within 9 May 2023
16:00 hours (CEST). Virtual participants need to be logged in to the meeting
before 16:00 hours (CEST) 22 May 2023.

All shareholders will receive a reference number and a pin code required for
registration through the company’s website. Reference number and pin code will
be received either by VPS Investor Service or by post depending if the
shareholder is registered as electronical user.
We encourage all shareholders to register as electronical user in VPS.

• END -

AboutBerGenBioASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections.

BerGenBiois based in Bergen, Norway with a subsidiary in Oxford, UK. The company
is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information,
visit?www.bergenbio.com

Contacts

Martin Olin, CEO, BerGenBio ASA
ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[Tekspert]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @Roc (59 likes)

@Roc

Grattis til BGBIO nye data på BEM

2. @anon8907229 (49 likes)

@anon8907229

Det har vært en veldig økning i nye AXL-hemmere under utvikling de siste årene, det er for meg en bekreftelse på det store potensialet innen AXL-hemming.

3. @Hotdog (45 likes)

@Hotdog

NewsWeb

Resten av topp 10:

4. @Matadoren (43 likes)

5. @drdr (38 likes)

6. @stAMy (27 likes)

7. @Zuba (26 likes)

8. @Bonus (23 likes)

9. @PankPinter (19 likes)

10. @keislar (17 likes)

Gratulerer!

[TekBot]

Financial calendar

Financial calendar for BerGenBio ASA

FINANCIAL YEAR 2022
…

Vis børsmeldingen

22.05.2023 - Annual General Meeting

FINANCIAL YEAR 2023

23.08.2023 - Half-yearly Report

22.06.2023 - Quarterly Report - Q1
14.11.2023 - Quarterly Report - Q3
15.02.2024 - Quarterly Report - Q4

This information is published pursuant to the requirements set out in the Continuing obligations.

Kilde

[TekBot]

BerGenBio to hold business update conference call

• Management to provide clinical and financial updates, and outline proposed
  rights issue -

…

Vis børsmeldingen

• Webcast will take place on Monday, May 15, 2023, at 10 a.m. CEST -

BERGEN, Norway, May 9, 2023 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, today announced that it will hold a business update
conference call on Monday, May 15, 2023, at 10 a.m. CEST. BerGenBio’s senior
management team will provide a briefing via a webcast presentation on the
Company’s website, followed by a Q&A session.

Topics to be addressed during the presentation include:

Proposed Rights Issue: The Company announced on April 25, 2023, its intentions
to carry out a partially underwritten rights issue to raise gross proceeds of up
to NOK 250 million.

A Q&A document pertaining to the rights issue can from today be found in the
General Meetings (General Meetings - BerGenBio) portion
of the Investors section of www.bergenbio.com.

BGBC008 Additional Data: Additional results of pre-planned analyses from the
Phase 2 BGBC008 trial evaluating bemcentinib in combination with pembrolizumab
in 2L+ NSCLC patients will be presented.

BGBC003 Topline Data: Topline data will be presented from the Phase 2 BGBC003
trial evaluating bemcentinib in combination with chemotherapy in patients with
AML and as a single agent in patients with MDS.

Financial Update: An update on the Company’s key financial numbers will be
provided as part of the business update.

Full first quarter 2023 financial results report will currently not be
prioritized and release will be delayed to 22 June 2023.

The webcast
link (https://channel.royalcast.com/landingpage/hegnarmedia/20230515_3/) will be
available at www.bergenbio.com in the Investors/Financial Reports section.

A recording will be available shortly after the webcast has finished.

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / Media Relations

Graham Morrell

graham.morrell@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

+47 90 55 16 98

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BERGENBIO ASA - Terms of the partially underwritten rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.
PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

Bergen, 20 May 2023: Reference is made to the stock exchange announcement
published by BerGenBio ASA (the “Company”) on 25 April 2023, regarding a
proposed partially underwritten rights issue of shares (the “New Shares”) with
preferential rights for existing shareholders (the “Rights Issue”), which is
subject to the approval by the annual general meeting of the Company to be held
at 16:00 (CEST) on 22 May 2023 (the “AGM”) and the notice to the AGM published
on 28 April 2023.

The Company’s board of directors has today, on 20 May 2023, based on a
recommendation from Arctic Securities AS and Carnegie AS (acting as “Managers”
in the Rights Issue), determined the following proposed (i) subscription price,
(ii) number of New Shares, (iii) share capital increase pertaining to the Rights
Issue and (iv) number of warrants:

. The subscription price is proposed to be NOK 0.10 per New Share,
based on a theoretical ex rights price (TERP) of NOK 0.15880 of the Company’s
shares calculated on the basis of (i) the volume-weighted average price (VWAP)
of the Company’s shares on Oslo Børs in the three last trading days’ prior to
the AGM of NOK 1.81669 and (ii) the assumed issue of the maximum number of New
Shares in the Rights Issue (equal to the number of subscription rights to be
issued);

. The share capital of the Company is proposed to be increased by
minimum NOK 168.75 million and maximum NOK 250 million through the issue of
minimum 1,687,500,000 New Shares and maximum 2,500,000,000 New Shares,
representing a ratio of 28.197440 New Shares per each existing share (assuming
issue of the maximum number of New Shares); and

. The number of warrants to be issued is proposed to be minimum
843,750,000and maximum 1,250,000,000, depending on the final number of New
Shares issued. Subscribers in the Rights Issue will for every two New Shares
allocated and paid receive one warrant, which will give the right to subscribe
for one new share in the Company.

The Company will raise between NOK 175 million and NOK 250 million in gross
proceeds in connection with the Rights Issue (of which up to NOK 6.25 million
may be by way of a loan granted by Meteva AS, please see below).

Each existing shareholder as of 22 May 2023 (and being registered as such in
Euronext Securities Oslo, the Norwegian Central Securities Depository, (the
“VPS”)) as at the expiry of 24 May 2023 (the record date) will be granted
28.197440 subscription rights for each share in the Company registered as held
by the shareholder. The number of subscription rights granted to each existing
shareholder will be rounded down to the nearest whole subscription right. Each
subscription right will, subject to applicable securities laws, give the right
to subscribe for and be allocated one (1) New Share in the Rights Issue.

The proposal to increase the share capital of the Company as set out in the
notice of the AGM dated 28 April 2023 will be adjusted to reflect the (i)
subscription price, (ii) the number of new shares and (iii) the share capital
increase pertaining to the Rights Issue as set out above. The proposal to issue
warrants as set out in the notice of the AGM will be adjusted to reflect the
number of warrants to be issued as set out above. For further information
regarding the Rights Issue, see the notice of the AGM available on
www.bergenbio.com.

Certain existing shareholders and external investors (jointly the
“Underwriters”) have underwritten NOK 175 million of the Rights Issue, subject
to potential reduction for Meteva AS as described below. Certain existing
shareholders have also pre-committed to subscribe in the Rights Issue, including
Meteva AS and Investinor Direkte AS which have pre-committed to subscribe for
NOK 65 million and NOK 17.5 million, respectively, which is included in the
underwriting amount of NOK 175 million. In addition, management and board
members in the Company will subscribe for New Shares in the Rights Issue with an
aggregate subscription price of at least NOK 0.5 million. Any New Shares
subscribed in the Rights Issue will reduce the underwriting commitment of the
Underwriters but not pre -commitments from existing shareholders.

Each Underwriter is entitled to an underwriting fee of 12% of its respective
underwriting obligation, to be settled in cash or new shares in the Company
issued at the subscription price in the Rights Issue, or through a combination
of cash and new shares, at the Underwriter’s election.

The Underwriters have undertaken to vote any shares held by them at the time of
the AGM in favour of the Rights Issue.

Meteva AS’ underwriting and pre-commitment to subscribe for New Shares are
limited such that Meteva AS’ holding of shares in the Company shall not exceed
1/3, and any remaining underwriting and pre-commitment shall be satisfied in the
form of a convertible loan from Meteva AS. Such convertible loan shall be
convertible into new shares in the Company at a conversion price equal to the
subscription price in the Rights Issue and otherwise on terms similar to those
in the existing loan agreement between the Company and Meteva AS announced
through the Company’s stock exchange announcement dated 25 October 2022 (the
“Meteva Loan”).

The Underwriters’ obligations to subscribe and pay for the New Shares allocated
to them in accordance with the underwriting agreements are conditional upon the
following conditions: (i) the Underwriters having underwritten NOK 175 million
of the gross proceeds of the Rights Issue, adjusted for the Meteva Loan, if
applicable, (ii) the AGM validly having approved the Rights Issue including the
subscription price, (iii) the Company having published a prospectus (the
“Prospectus”) in relation to the Rights Issue approved by the Norwegian
Financial Supervisory Authority, (iv) the Company having issued on the date of
the Prospectus, a declaration of completeness and indemnity for the benefit of
the Managers in a form satisfactory to the Managers in their sole discretion and
(v) save as disclosed in the Prospectus, no change, event, effect, or condition
shall have occurred that has or would have, individually or in the aggregate, an
effect on the current or future business, assets, liabilities, liquidity,
solvency or funding position or condition (financial or otherwise) or results of
the Company and its subsidiaries taken as a whole, which in the good faith
opinion of the Managers is so material and adverse as to make it impracticable
or inadvisable to proceed with the Rights Issue or the delivery of the New
Shares on the terms and in the manner contemplated in the Prospectus.

If the Rights Issue is withdrawn, all subscription rights will lapse without
value, any subscriptions for, and allocations of, New Shares that have been made
will be disregarded and any payments for New Shares made will be returned to the
subscribers without interest or any other compensation. The lapsing of
subscription rights will be without prejudice to the validity of any trades in
subscription rights, and investors will not receive any refund or compensation
in respect of subscription rights purchased in the market.

The full terms and conditions of the Rights Issue will be included in the
Prospectus, which will be published prior to the commencement of the
subscription period in the Rights Issue, expected to take place from 30 May 2023
to 13 June 2023 at 16:30 (CEST).

Arctic Securities AS and Carnegie AS are acting as managers for the Rights
Issue. Advokatfirmaet Thommessen AS is acting as legal counsel to the Company.

For further information about the Company, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / Media Relations

Graham Morrell

graham.morrell@bergenbio.com

Media Relations Norway

Jan Lilleby

jl@lillebyfrisch.no

+47 90 55 16 98

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation (MAR) and is subject to the disclosure requirements
pursuant to MAR article 17 and section 5-12 of the Norwegian Securities Trading
Act.

This stock exchange announcement was published by Rune Skeie, CFO on 20 May 2023
at 12:00 CEST on behalf of the Company.

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com.

---

• IMPORTANT INFORMATION -

This announcement does not constitute an offer of securities for sale or a
solicitation of an offer to purchase securities of the Company in the United
States or any other jurisdiction. Copies of this document may not be sent to
jurisdictions, or distributed in or sent from jurisdictions, in which this is
barred or prohibited by law. The securities of the Company may not be offered or
sold in the United States absent registration or an exemption from registration
under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”).

The securities of the Company have not been, and will not be, registered under
the U.S. Securities Act. Any sale in the United States of the securities
mentioned in this communication will be made solely to “qualified institutional
buyers” as defined in Rule 144A under the U.S. Securities Act. No public
offering of the securities will be made in the United States.

Any offering of the securities referred to in this announcement will be made by
means of a prospectus (the “Prospectus”) which will be prepared and which is
subject to the approval by the Norwegian Financial Supervisory Authority. This
announcement is an advertisement and is not a prospectus for the purposes of
Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14
June 2017 on prospectuses to be published when securities are offered to the
public or admitted to trading on a regulated market, and repealing Directive
2003/71/EC (as amended) as implemented in any EA Member State (the “Prospectus
Regulation”). Investors should not subscribe for any securities referred to in
this announcement except on the basis of information contained in the
Prospectus. Copies of the Prospectus will, following publication, be available
from the Company’s registered office and, subject to certain exceptions, on the
websites of the Managers.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation, i.e., only to investors who can receive the offer without
an approved prospectus in such EEA Member State.

In the United Kingdom, this communication is only addressed to and is only
directed at Qualified Investors who (i) are investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling
within Article 49(2)(a) to (d) of the Order (high net worth companies,
unincorporated associations, etc.) (all such persons together being referred to
as “Relevant Persons”). These materials are directed only at Relevant Persons
and must not be acted on or relied on by persons who are not Relevant Persons.
Any investment or investment activity to which this announcement relates is
available only to Relevant Persons and will be engaged in only with Relevant
Persons. Persons distributing this communication must satisfy themselves that it
is lawful to do so.

This document is not for publication or distribution in, directly or indirectly,
Australia, Canada, Japan, the United States or any other jurisdiction in which
such release, publication or distribution would be unlawful, and it does not
constitute an offer or invitation to subscribe for or purchase any securities in
such countries or in any other jurisdiction. In particular, the document and the
information contained herein should not be distributed or otherwise transmitted
into the United States or to publications with a general circulation in the
United States of America.

The Managers are acting for the Company in connection with the Rights Issue and
no one else and will not be responsible to anyone other than the Company for
providing the protections afforded to their respective clients or for providing
advice in relation to the Rights Issue or any transaction or arrangement
referred to in this announcement.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as “anticipate”, “believe”,
“continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar
expressions. The forward-looking statements in this release are based upon
various assumptions, many of which are based, in turn, upon further assumptions.
Although the Company believes that these assumptions were reasonable when made,
these assumptions are inherently subject to significant known and unknown risks,
uncertainties, contingencies and other important factors which are difficult or
impossible to predict and are beyond its control. Such risks, uncertainties,
contingencies and other important factors could cause actual events to differ
materially from the expectations expressed or implied in this release by such
forward-looking statements. The information, opinions and forward-looking
statements contained in this announcement speak only as at its date and are
subject to change without notice. This announcement is made by and is the
responsibility of, the Company. Neither the Managers nor any of their respective
affiliates makes any representation as to the accuracy or completeness of this
announcement and none of them accepts any responsibility for the contents of
this announcement or any matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. No reliance may be
placed for any purpose on the information contained in this announcement or its
accuracy, fairness or completeness. Neither the Managers nor any of their
respective affiliates accepts any liability arising from the use of this
announcement.

Kilde

[TekBot]

BerGenBio ASA - Updated key information relating to the preferential rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE
PEOPLE’S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE
…

Vis børsmeldingen

DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE.

Reference is made to the stock exchange announcement published by BerGenBio ASA
(the “Company”) on 25 April 2023 with key information relating to the
preferential rights issue in the Company.

Date on which the terms and conditions of the preferential rights issue were
announced: 25 April 2023 and 20 May 2023

Last day including right: 22 May 2023

Ex-date: 23 May 2023

Record Date: 24 May 2023

Date of approval: 22 May 2023

Maximum number of new shares: 2,500,000,000

Subscription price: NOK 0.10

Ratio preferential rights: Each existing shareholder as of 22 May 2023 (and
being registered as such in Euronext Securities Oslo, the Norwegian Central
Securities Depository, (the VPS) as at the expiry of 24 May 2023 (the record
date)) will be granted 28.197440 subscription rights for each share registered
as held by the shareholder. The number of subscription rights granted to each
existing shareholder will be rounded down to the nearest whole subscription
right.

Subscription ratio: 1:1 (number of new shares per subscription right)

Managers: Arctic Securities AS and Carnegie AS

Will the rights be listed: Yes (ticker code “BGBIT”)

ISIN for the preferential rights: ISIN NO 0012921180

Other information: The subscribers in the Rights Issue will without cost be
allocated one warrant (Nw. “frittstående tegningsrett”) issued by the Company
for every two new shares allocated to, and paid by, them in the Rights Issue.
The number of warrants to be issued will be minimum 843,750,000 and maximum
1,250,000,000. Each warrant will give the holder a right to subscribe for one
new share in the Company at a subscription price equal to the volume-weighted
average price (VWAP) of the Company’s shares on the Oslo Stock Exchange on the
three last trading days prior to the first date on which the holder can exercise
the warrant in each exercise period (as described below) less 30%, but in any
event not exceeding the subscription price in the Rights Issue plus 30% (i.e.
NOK 0.13. The warrants may be exercised during two exercise periods: (i) within
the first 14 days after the Company’s announcement of its Q3 2023 quarterly
financial report and (ii) from 1 April 2024 to 14 April 2024.

The preferential rights issue is subject to approval by the annual general
meeting of the Company, which will be held on 22 May 2023.

This information is published in accordance with the requirements of the
Continuing Obligations.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / Media Relations

Graham Morrell

graham.morrell@bergenbio.com

For information about the Rights Issue please contact the Managers:

Arctic Securities AS, tel.: + 47 21 01 30 40

Carnegie AS, tel.: +47 22 00 93 40

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate bemcentinib a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com.

Kilde